Achieving a Maximally Tolerated β-Blocker Dose in Heart Failure Patients: Is There Room for Improvement?

[1]  Volkmar Falk,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.

[2]  G. Fonarow,et al.  Discharge heart rate and β-blocker dose in patients hospitalized with heart failure: Findings from the OPTIMIZE-HF registry. , 2016, American heart journal.

[3]  I. Piña,et al.  Heart Rate or Beta-Blocker Dose? Association With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction: Results From the HF-ACTION Trial. , 2016, JACC. Heart failure.

[4]  Deepak L. Bhatt,et al.  Heart Rate at Hospital Discharge in Patients With Heart Failure Is Associated With Mortality and Rehospitalization , 2015, Journal of the American Heart Association.

[5]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[6]  Emma P Bray,et al.  Effect of self-monitoring and medication self-titration on systolic blood pressure in hypertensive patients at high risk of cardiovascular disease: the TASMIN-SR randomized clinical trial. , 2014, JAMA.

[7]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[8]  W. Koch,et al.  Adrenergic Nervous System in Heart Failure: Pathophysiology and Therapy , 2013, Circulation research.

[9]  C. O'connor,et al.  Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). , 2013, The American journal of cardiology.

[10]  Biykem Bozkurt,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[11]  W. Kraus,et al.  Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial. , 2012, Journal of the American College of Cardiology.

[12]  J. Cleland,et al.  Heart rate achieved or beta‐blocker dose in patients with chronic heart failure: which is the better target? , 2012, European journal of heart failure.

[13]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[14]  D. Lanfear,et al.  Pharmacogenetics in Chronic Heart Failure: New Developments and Current Challenges , 2012, Current Heart Failure Reports.

[15]  R. Wachter,et al.  Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial , 2011, European journal of heart failure.

[16]  M. Cheitlin.  Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2011 .

[17]  Michael Böhm,et al.  Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2010, The Lancet.

[18]  Richard J McManus,et al.  Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial , 2010, The Lancet.

[19]  Nancy M Albert,et al.  HFSA 2010 Comprehensive Heart Failure Practice Guideline. , 2010, Journal of cardiac failure.

[20]  Natasha Wiebe,et al.  Meta-analysis: -Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure , 2009, Annals of Internal Medicine.

[21]  G. Fonarow,et al.  Influence of patient age and sex on delivery of guideline-recommended heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. , 2009, American heart journal.

[22]  C. O'connor,et al.  Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). , 2008, The American journal of cardiology.

[23]  R. Ferrari,et al.  Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial , 2008, The Lancet.

[24]  S. Nonen,et al.  Chronic heart failure: β-blockers and pharmacogenetics , 2008, European Journal of Clinical Pharmacology.

[25]  B. Massie,et al.  β-Blocker dosing in community-based treatment of heart failure , 2007 .

[26]  J. Cleland,et al.  The effect of altering heart rate on ventricular function in patients with heart failure treated with beta-blockers. , 2006, American heart journal.

[27]  B. Silke.  Beta-blockade in CHF : pathophysiological considerations , 2006 .

[28]  W. Herman,et al.  Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial. , 2006, Diabetes care.

[29]  P. Poole‐Wilson,et al.  Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. , 2005, European heart journal.

[30]  A. Laupacis,et al.  Risk-treatment mismatch in the pharmacotherapy of heart failure. , 2005, JAMA.

[31]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[32]  Douglas L Mann,et al.  Mechanisms and models in heart failure: the biomechanical model and beyond. , 2005, Circulation.

[33]  L. Luddington,et al.  Success of a multidisciplinary heart failure clinic for initiation and up‐titration of key therapeutic agents , 2005, European Journal of Heart Failure.

[34]  A. Cohen-Solal,et al.  Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). , 2005, European heart journal.

[35]  S. Gottlieb,et al.  What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). , 2005, Journal of the American College of Cardiology.

[36]  P. Poole‐Wilson,et al.  Exchange of β‐blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial) , 2004, European journal of heart failure.

[37]  D. Atar,et al.  Tolerability of β-Blocker Initiation and Titration with Bisoprolol and Carvedilol in Congestive Heart Failure – A Randomized Comparison , 2004, Cardiology.

[38]  P. Armstrong,et al.  The use of beta-blockers in a tertiary care heart failure clinic: dosing, tolerance, and outcomes. , 2004, Archives of internal medicine.

[39]  P. Armstrong,et al.  The Use of -Blockers in a Tertiary Care Heart Failure Clinic , 2004 .

[40]  P. Poole‐Wilson,et al.  Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial , 2003, The Lancet.

[41]  Paul A. Heidenreich,et al.  Improving Guideline Adherence: A Randomized Trial Evaluating Strategies to Increase &bgr;-Blocker Use in Heart Failure , 2003, Circulation.

[42]  R. Belue,et al.  Tolerability to beta-blocker therapy among heart failure patients in clinical practice. , 2003, Journal of cardiac failure.

[43]  T. Simon,et al.  Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study(CIBIS II). , 2003, European heart journal.

[44]  P. Macdonald,et al.  Women miss out on coronary care , 2003, Heart.

[45]  P. Poole‐Wilson,et al.  Mode of death in heart failure: findings from the ATLAS trial , 2003, Heart.

[46]  Javed Butler,et al.  Outpatient adherence to beta-blocker therapy after acute myocardial infarction. , 2002, Journal of the American College of Cardiology.

[47]  E. Salpeter,et al.  Cardioselective -Blockers in Patients with Reactive Airway Disease , 2002, Annals of Internal Medicine.

[48]  D. DeMets,et al.  Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study , 2002, Circulation.

[49]  Robert J. Lefkowitz,et al.  Seven-transmembrane-spanning receptors and heart function , 2002, Nature.

[50]  M. Domanski,et al.  A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. , 2001, The New England journal of medicine.

[51]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[52]  PhilippeLechat,et al.  Heart Rate and Cardiac Rhythm Relationships With Bisoprolol Benefit in Chronic Heart Failure in CIBIS II Trial , 2001 .

[53]  A. Mallet,et al.  Heart Rate and Cardiac Rhythm Relationships With Bisoprolol Benefit in Chronic Heart Failure in CIBIS II Trial , 2001, Circulation.

[54]  T. R. I. Nvestigators.  A TRIAL OF THE BETA-BLOCKER BUCINDOLOL IN PATIENTS WITH ADVANCED CHRONIC HEART FAILURE , 2001 .

[55]  M. Bristow.  β-Adrenergic Receptor Blockade in Chronic Heart Failure , 2000 .

[56]  ICHAEL,et al.  THE EFFECT OF CARVEDILOL ON MORBIDITY AND MORTALITY IN PATIENTS WITH CHRONIC HEART FAILURE , 2000 .

[57]  E Kristal-Boneh,et al.  The association of resting heart rate with cardiovascular, cancer and all-cause mortality. Eight year follow-up of 3527 male Israeli employees (the CORDIS Study) , 2000, European heart journal.

[58]  M. Bristow.  b-Adrenergic Receptor Blockade in Chronic Heart Failure , 2000 .

[59]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[60]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[61]  K. Adams,et al.  Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. , 1996, Circulation.